乳腺癌血管生成拟态和免疫微环境关系的初步探索

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1461 KB)
输出: BibTeX | EndNote (RIS)

摘要目的了解乳腺癌临床病理特征和血管生成拟态(VM)及CD8⁺T细胞表达情况的关系,探索VM与肿瘤微环境(TME)的相关性。方法 60例乳腺癌组织标本制备成组织芯片,应用CD31/PAS双重染色法检测VM表达情况,应用免疫组织化学染色法(IHC)计数CD8⁺T细胞的数量并计算表达率,分析乳腺癌临床病理特征与两者的关系,了解VM与CD8⁺T细胞的相关性。结果 60例乳腺癌组织样本中VM阳性检出24例(40%),病理分级G3的VM阳性检出率(63.2%)高于G1-2(29.3%),差异有统计学意义(χ²＝6.213,P=0.013)。Ⅲ期VM阳性检出率(54.5%)高于Ⅰ期(16.7)和Ⅱ期(45.0%),差异有统计学意义(χ²＝6.231,P=0.044);三阴型VM阳性表达(60.0%)高于其他分子分型(12%),差异有统计学意义(χ²＝14.0,P＜0.001);浸润性导管癌与其他组织分型在VM检出率上的差异无统计学意义;年龄≥40岁与＜40岁的人群在VM检出率上差异无统计学意义。CD8⁺T细胞阳性表达检出26例(43.3%),三阴型乳腺癌(TNBC)中CD8⁺T细胞阳性表达(28.6%)低于其他分子分型(64.0%),差异有统计学意义(χ²＝7.454,P=0.006);年龄、组织分型、病理分级、临床分期在CD8⁺T细胞表达上的差异无统计学意义。全样本中VM阴性和阳性在CD8⁺T细胞表达与否上的差异有统计学意义(χ²＝11.584,P＜0.001),但在TNBC样本中差异无统计学意义。结论 VM形成在分期晚和分化差的乳腺癌中更为多见,尤其在TNBC中比例更高,CD8⁺T细胞更多见于非TNBC的人群。有显著VM形成的乳腺癌中,CD8⁺ T淋巴细胞往往较少。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄竞
	栾飞扬
	马欣越
	安亦扬
	胡思睿
	刘希
	杨谨
	董丹凤

关键词 ：乳腺癌, 血管生成拟态, 肿瘤免疫微环境, CD8⁺T淋巴细胞

Abstract：Objective To understand the relationship between the clinicopathological features of breast cancer and the expression of vasculogenic mimicry (VM ) and CD8+T cells. Futher to explore the correlation between VM and immune microenvironment. Methods 60 cases of breast cancer tissue samples were collected to make tissue chip. The expression of VM was detected by CD31/PAS double staining. IHC was used to assess the expression of CD8⁺T cells.The relationship among VM expression, CD8⁺T cell expression and clinicopathological characteristics were analyzed, so as to infer the relationship between VM and CD8⁺T cells. Results Among 60 cases of breast cancer tissue samples, VM was detected in 24 cases (40%). The positive rate of VM in pathlogical grade G3 was 63.2%, while it was 29.3% in tissues from G1 and G2. The difference was statistically significant (χ²=6.213,P=0.013).The positive detection rate of VM in stage Ⅲ (54.5%) was significantly higher than that in stage Ⅰ/Ⅱ (χ²=6.231,P=0.044). The positive expression of VM in triple negative type was significantly higher than that in other molecular types, and the difference was statistically significant (χ²=14.0,P＜0.001).There was no significant difference in the detection rate of VM with age and histological types.The positive expression of CD8⁺T cells was detected in 26 cases (43.3%). The positive expression of CD8⁺T cells in triple negative breast cancer (TNBC) was significantly lower than that in other molecular subtypes, and the difference was statistically significant (χ²=7.454,P=0.006). There was no significant difference in the expression of CD8⁺ T cells among age, histological type, pathological grade and clinical stage. There was a significant difference in the expression of CD8⁺ T cells between VM negative and positive in the whole samples (χ²=11.584,P＜0.001), but there was no significant difference in TNBC samples (χ²=1.313,P=0.252). Conclusion VM formation is more common in advanced and poorly differentiated breast cancer, especially in TNBC, and CD8⁺T cells are more common in non-TNBC. In breast cancer with significant VM formation, CD8⁺T lymphocytes are often less.

Key words： breast cancer vasculogenic mimicry tumor immune microenvironment CD8⁺T lymphocytes

收稿日期: 2024-09-12

ZTFLH:

R737

基金资助:国家自然科学基金项目(82002803);陕西省重点研发计划(2020SF-029);吴阶平医学基金项目(320.6750.2021-10-84)

通讯作者: 董丹凤,E-mail:qiwudanfeng@163.com

作者简介: 黄竞,硕士研究生。

引用本文:

黄竞, 栾飞扬, 马欣越, 安亦扬, 胡思睿, 刘希, 杨谨, 董丹凤. 乳腺癌血管生成拟态和免疫微环境关系的初步探索[J]. 武警医学, 2025, 36(1): 16-20. HUANG Jing, LUAN Feiyang, MA Xinyue, AN Yiyang, HU Sirui, LIU Xi, YANG Jin, DONG Danfeng. Preliminary exploration of the relationship between vasculogenic mimicry and immune microenvironment in breast cancer. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(1): 16-20.

链接本文:

https://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 https://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2025/V36/I1/16

[1]	Siegel R L,Giaquinto A N,Jemal A.Cancer statistics, 2024[J].CA Cancer J Clin,2024,74(1):12-49.
[2]	郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.?
[3]	Bejarano L,Jordāo M J C,Joyce J A.Therapeutic targeting of the tumor microenvironment[J].Cancer Discov,2021,11(4):933-959.
[4]	Murai T,Matsuda S.Targeting the PI3K-Akt-mTOR signaling pathway involved in vasculogenic mimicry promoted by cancer stem cells[J].Am J Cancer Res,2023,13(11):5039-5046.
[5]	Chavoshi H,Poormolaie N,Vahedian V,et al.Vascular mimicry: a potential therapeutic target in breast cancer[J].Pathol Res Pract,2022,234:153922.
[6]	Zhang L,Wu J,Yin W W,et al.Vasculogenic mimicry-associated novel gene signature predicted prognosis and response to immunotherapy in lung adenocarcinoma[J].Pathol Res Pract,2024,253:155048.
[7]	Lv B,Wang Y,Ma D,et al.Immunotherapy: reshape the tumor immune microenvironment[J].Front Immunol,2022,13:844142.
[8]	Murugesan A,Bharath C,Balakrishnan S,et al.Expression of HIF-1α and nestin in oral squamous cell carcinoma and its association with vasculogenic mimicry[J].J Cancer Res Ther,2024,20(1):176-180.
[9]	Hoxha I,Sadiku F,Hoxha L,et al.Breast cancer and lifestyle factors: umbrella review[J].Hematol Oncol Clin North Am,2024,38(1):137-170.
[10]	Liu Y, He X, Yang Y I. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer[J].J Biosci,2024,49(4):19.
[11]	徐可佩,方晓政,林怡,等.MRI影像组学与乳腺癌肿瘤新生血管相关性研究[J].磁共振成像,2022,13(8):146-149.
[12]	Wei X,Chen Y, Jiang X,et al.Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments[J].Mol Cancer,2021,20(1):7.
[13]	Morales-Guadarrama G,Méndez-Pérez E A,García-Quiroz J,et al.The inhibition of the FGFR/PI3K/Akt Axis by AZD4547 disrupts the proangiogenic microenvironment and vasculogenic mimicry arising from the interplay between endothelial and triple-negative breast cancer cells[J].Int J Mol Sci,2023,24(18):13770.
[14]	Jung E,Lee Y H, Ou S,et al.EGR1 regulation of vasculogenic mimicry in the MDA-MB-231 triple-negative breast cancer cell line through the upregulation of KLF4 expression[J].Int J Mol Sci,2023,24(18):14375.
[15]	Wu S Y,Xu Y,Chen L,et al.Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the Future-C-Plus trial[J].Mol Cancer,2022,21(1):84.
[16]	Lin F,Ke Z B, Xue Y T,et al.A novel CD8+T cell-related gene signature for predicting the prognosis and immunotherapy efficacy in bladder cancer[J].Inflamm Res,2023,72(8):1665-1687.
[17]	Lin X,Long S,Yan C,et al.Therapeutic potential of vasculogenic mimicry in urological tumors[J].Front Oncol,2023,13:1202656.
[18]	Dudley A C,Griffioen A W.Pathological angiogenesis: mechanisms and therapeutic strategies[J].Angiogenesis,2023,26(3):313-347.